Literature DB >> 26972001

Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins.

Gaspar J Kitange1, Ann C Mladek2, Mark A Schroeder2, Jenny C Pokorny2, Brett L Carlson2, Yuji Zhang3, Asha A Nair3, Jeong-Heon Lee4, Huihuang Yan3, Paul A Decker3, Zhiguo Zhang4, Jann N Sarkaria2.   

Abstract

Here we provide evidence that RBBP4 modulates temozolomide (TMZ) sensitivity through coordinate regulation of two key DNA repair genes critical for recovery from TMZ-induced DNA damage: methylguanine-DNA-methyltransferase (MGMT) and RAD51. Disruption of RBBP4 enhanced TMZ sensitivity, induced synthetic lethality to PARP inhibition, and increased DNA damage signaling in response to TMZ. Moreover, RBBP4 silencing enhanced TMZ-induced H2AX phosphorylation and apoptosis in GBM cells. Intriguingly, RBBP4 knockdown suppressed the expression of MGMT, RAD51, and other genes in association with decreased promoter H3K9 acetylation (H3K9Ac) and increased H3K9 tri-methylation (H3K9me3). Consistent with these data, RBBP4 interacts with CBP/p300 to form a chromatin-modifying complex that binds within the promoter of MGMT, RAD51, and perhaps other genes. Globally, RBBP4 positively and negatively regulates genes involved in critical cellular functions including tumorigenesis. The RBBP4/CBP/p300 complex may provide an interesting target for developing therapy-sensitizing strategies for GBM and other tumors.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MGMT; RBBP4; glioblastoma; resistance; temozolomide

Mesh:

Substances:

Year:  2016        PMID: 26972001      PMCID: PMC4805508          DOI: 10.1016/j.celrep.2016.02.045

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  50 in total

1.  BRCA1 interacts with components of the histone deacetylase complex.

Authors:  R I Yarden; L C Brody
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.

Authors:  Gaspar J Kitange; Ann C Mladek; Brett L Carlson; Mark A Schroeder; Jenny L Pokorny; Ling Cen; Paul A Decker; Wenting Wu; Gwen A Lomberk; Shiv K Gupta; Raul A Urrutia; Jann N Sarkaria
Journal:  Clin Cancer Res       Date:  2012-06-06       Impact factor: 12.531

Review 3.  Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.

Authors:  Roel H Wilting; Jan-Hermen Dannenberg
Journal:  Drug Resist Updat       Date:  2012-02-20       Impact factor: 18.500

4.  Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.

Authors:  Gaspar J Kitange; Brett L Carlson; Mark A Schroeder; Patrick T Grogan; Jeff D Lamont; Paul A Decker; Wenting Wu; C David James; Jann N Sarkaria
Journal:  Neuro Oncol       Date:  2008-10-24       Impact factor: 12.300

Review 5.  Mechanisms of chemoresistance to alkylating agents in malignant glioma.

Authors:  Jann N Sarkaria; Gaspar J Kitange; C David James; Ruth Plummer; Hilary Calvert; Michael Weller; Wolfgang Wick
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

6.  Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs.

Authors:  Wynand P Roos; Teodora Nikolova; Steve Quiros; Steffen C Naumann; Olivia Kiedron; Małgorzata Z Zdzienicka; Bernd Kaina
Journal:  DNA Repair (Amst)       Date:  2008-10-21

7.  Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.

Authors:  Susan C Short; Silvia Giampieri; Mulugeta Worku; Marisa Alcaide-German; George Sioftanos; Sara Bourne; Ka Ian Lio; Maya Shaked-Rabi; Christine Martindale
Journal:  Neuro Oncol       Date:  2011-03-01       Impact factor: 12.300

8.  Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.

Authors:  Lucio Tentori; Lucia Ricci-Vitiani; Alessia Muzi; Fabio Ciccarone; Federica Pelacchi; Roberta Calabrese; Daniele Runci; Roberto Pallini; Paola Caiafa; Grazia Graziani
Journal:  BMC Cancer       Date:  2014-03-05       Impact factor: 4.430

9.  Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition.

Authors:  Yujie Tang; Sharareh Gholamin; Simone Schubert; Minde I Willardson; Alex Lee; Pratiti Bandopadhayay; Guillame Bergthold; Sabran Masoud; Brian Nguyen; Nujsaubnusi Vue; Brianna Balansay; Furong Yu; Sekyung Oh; Pamelyn Woo; Spenser Chen; Anitha Ponnuswami; Michelle Monje; Scott X Atwood; Ramon J Whitson; Siddhartha Mitra; Samuel H Cheshier; Jun Qi; Rameen Beroukhim; Jean Y Tang; Rob Wechsler-Reya; Anthony E Oro; Brian A Link; James E Bradner; Yoon-Jae Cho
Journal:  Nat Med       Date:  2014-06-29       Impact factor: 53.440

10.  Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells.

Authors:  Gai Yan; Mark S Eller; Courtney Elm; Cecilia A Larocca; Byungwoo Ryu; Izabela P Panova; Beverley M Dancy; Erin M Bowers; David Meyers; Lisa Lareau; Philip A Cole; Sean D Taverna; Rhoda M Alani
Journal:  J Invest Dermatol       Date:  2013-04-18       Impact factor: 8.551

View more
  23 in total

1.  Glioblastoma Cancer Stem Cells Evade Innate Immune Suppression of Self-Renewal through Reduced TLR4 Expression.

Authors:  Alvaro G Alvarado; Praveena S Thiagarajan; Erin E Mulkearns-Hubert; Daniel J Silver; James S Hale; Tyler J Alban; Soumya M Turaga; Awad Jarrar; Ofer Reizes; Michelle S Longworth; Michael A Vogelbaum; Justin D Lathia
Journal:  Cell Stem Cell       Date:  2017-01-12       Impact factor: 24.633

2.  Reduced expression of DNA repair genes and chemosensitivity in 1p19q codeleted lower-grade gliomas.

Authors:  Lei Tang; Lu Deng; Harrison X Bai; James Sun; Natalie Neale; Jing Wu; Yinyan Wang; Ken Chang; Raymond Y Huang; Paul J Zhang; Xuejun Li; Bo Xiao; Ya Cao; Yongguang Tao; Li Yang
Journal:  J Neurooncol       Date:  2018-06-19       Impact factor: 4.130

3.  Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma.

Authors:  Shuang G Zhao; Menggang Yu; Daniel E Spratt; S Laura Chang; Felix Y Feng; Michelle M Kim; Corey W Speers; Brett L Carlson; Ann C Mladek; Theodore S Lawrence; Jann N Sarkaria; Daniel R Wahl
Journal:  Neuro Oncol       Date:  2019-09-06       Impact factor: 12.300

4.  pH-Sensitive O6-Benzylguanosine Polymer Modified Magnetic Nanoparticles for Treatment of Glioblastomas.

Authors:  Zachary R Stephen; Rachel N Gebhart; Mike Jeon; Allison A Blair; Richard G Ellenbogen; John R Silber; Miqin Zhang
Journal:  Bioconjug Chem       Date:  2016-12-12       Impact factor: 4.774

5.  Sox9 directs divergent epigenomic states in brain tumor subtypes.

Authors:  Debosmita Sardar; Hsiao-Chi Chen; Amanda Reyes; Srinidhi Varadharajan; Antrix Jain; Carrie Mohila; Rachel Curry; Brittney Lozzi; Kavitha Rajendran; Alexis Cervantes; Kwanha Yu; Ali Jalali; Ganesh Rao; Stephen C Mack; Benjamin Deneen
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-15       Impact factor: 12.779

6.  RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma.

Authors:  Ann C Mladek; Huihuang Yan; Shulan Tian; Paul A Decker; Danielle M Burgenske; Katrina Bakken; Zeng Hu; Lihong He; Margaret A Connors; Brett L Carlson; Jonathan Wilson; Archana Bommi-Reddy; Andy Conery; Jeanette E Eckel-Passow; Jann N Sarkaria; Gaspar J Kitange
Journal:  Neuro Oncol       Date:  2022-08-01       Impact factor: 13.029

7.  Loss of RBBP4 results in defective inner cell mass, severe apoptosis, hyperacetylated histones and preimplantation lethality in mice†.

Authors:  Xiaosu Miao; Tieqi Sun; Holly Barletta; Jesse Mager; Wei Cui
Journal:  Biol Reprod       Date:  2020-06-23       Impact factor: 4.285

Review 8.  WD40 repeat domain proteins: a novel target class?

Authors:  Matthieu Schapira; Mike Tyers; Maricel Torrent; Cheryl H Arrowsmith
Journal:  Nat Rev Drug Discov       Date:  2017-10-13       Impact factor: 84.694

Review 9.  Bromodomain proteins: repairing DNA damage within chromatin.

Authors:  Li-Ya Chiu; Fade Gong; Kyle M Miller
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-10-05       Impact factor: 6.671

10.  Chronic treatment with cisplatin induces chemoresistance through the TIP60-mediated Fanconi anemia and homologous recombination repair pathways.

Authors:  Wen-Pin Su; Yen-Chih Ho; Cheng-Kuei Wu; Sen-Huei Hsu; Jia-Lin Shiu; Jheng-Cheng Huang; Song-Bin Chang; Wen-Tai Chiu; Jan-Jong Hung; Tsung-Lin Liu; Wei-Sheng Wu; Pei-Yu Wu; Wu-Chou Su; Jang-Yang Chang; Hungjiun Liaw
Journal:  Sci Rep       Date:  2017-06-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.